PMC:7060195 / 8548-9466
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 193 | 212-214 | Gene | denotes | S1 | |
| 194 | 417-420 | Gene | denotes | GSK | |
| 195 | 249-259 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 196 | 825-835 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 197 | 76-84 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T41 | 215-222 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T42 | 855-859 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T51 | 76-84 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T52 | 249-257 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T53 | 825-833 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T73 | 19-24 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T74 | 112-117 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T75 | 212-214 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T76 | 458-459 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T77 | 603-604 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T78 | 819-820 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T79 | 855-859 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
| T80 | 881-888 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T45 | 215-222 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T46 | 358-367 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
| T47 | 376-380 | Chemical | denotes | alum | http://purl.obolibrary.org/obo/CHEBI_74768 |
| T48 | 395-404 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
| T49 | 434-443 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T14 | 719-735 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T56 | 0-85 | Sentence | denotes | We can assume that virus-based vaccines should prove valuable in combatting COVID-19. |
| T57 | 86-306 | Sentence | denotes | In addition to the entire virus particle-associated inactivated or attenuated viral vaccines, the subunit candidates, such as S1 protein and/or the RBD element of SARS-CoV-2, are also valuable targets for vaccine design. |
| T58 | 307-599 | Sentence | denotes | Combining subunit vaccines with established or new adjuvants such as alum versus modern adjuvants such as the GSK AS series of adjuvants may represent a faster and safer strategy to move through early clinical development with the caveat that the protective efficacy may not be strong enough. |
| T59 | 600-757 | Sentence | denotes | As a result, immunizing the subunit vaccines with proper delivery platforms and immunization strategies to enhance the immune responses should be considered. |
| T60 | 758-918 | Sentence | denotes | We expect researchers who are racing against time will bring a new SARS-CoV-2-based vaccine from gene sequence to clinical testing in approximately 16–20 weeks. |